Colleen Kusy
Stock Analyst at Baird
(1.27)
# 2,697
Out of 4,479 analysts
25
Total ratings
37.04%
Success rate
-11.22%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CHRS Coherus BioSciences | Maintains: Outperform | $9 → $8 | $1.39 | +475.54% | 3 | Jul 1, 2024 | |
| OCS Oculis Holding AG | Maintains: Outperform | $35 → $37 | $11.87 | +211.71% | 3 | Jun 11, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | $32 | $21.70 | +47.47% | 1 | Jun 11, 2024 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $50 | $23.79 | +110.17% | 1 | May 2, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $7.52 | +232.45% | 1 | Mar 12, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $1 → $5 | $1.86 | +168.82% | 3 | Feb 29, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $73.00 | +43.84% | 1 | Feb 23, 2024 | |
| APLS Apellis Pharmaceuticals | Reiterates: Outperform | $81 | $34.98 | +131.56% | 4 | Feb 6, 2024 | |
| OCUL Ocular Therapeutix | Reiterates: Outperform | $18 | $6.68 | +169.46% | 3 | Sep 14, 2023 | |
| AGEN Agenus | Initiates: Outperform | $160 | $14.28 | +1,020.45% | 1 | Jun 6, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $17 → $14 | $0.80 | +1,650.00% | 1 | Aug 5, 2022 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $34 | $7.73 | +339.84% | 2 | Apr 7, 2022 | |
| SABS SAB Biotherapeutics | Initiates: Outperform | $230 | $2.86 | +7,941.96% | 1 | Nov 2, 2021 |
Coherus BioSciences
Jul 1, 2024
Maintains: Outperform
Price Target: $9 → $8
Current: $1.39
Upside: +475.54%
Oculis Holding AG
Jun 11, 2024
Maintains: Outperform
Price Target: $35 → $37
Current: $11.87
Upside: +211.71%
Enliven Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: $32
Current: $21.70
Upside: +47.47%
Spyre Therapeutics
May 2, 2024
Initiates: Outperform
Price Target: $50
Current: $23.79
Upside: +110.17%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $7.52
Upside: +232.45%
Mersana Therapeutics
Feb 29, 2024
Maintains: Neutral
Price Target: $1 → $5
Current: $1.86
Upside: +168.82%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $73.00
Upside: +43.84%
Apellis Pharmaceuticals
Feb 6, 2024
Reiterates: Outperform
Price Target: $81
Current: $34.98
Upside: +131.56%
Ocular Therapeutix
Sep 14, 2023
Reiterates: Outperform
Price Target: $18
Current: $6.68
Upside: +169.46%
Agenus
Jun 6, 2023
Initiates: Outperform
Price Target: $160
Current: $14.28
Upside: +1,020.45%
Karyopharm Therapeutics
Aug 5, 2022
Maintains: Outperform
Price Target: $17 → $14
Current: $0.80
Upside: +1,650.00%
Iovance Biotherapeutics
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $7.73
Upside: +339.84%
SAB Biotherapeutics
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $2.86
Upside: +7,941.96%